Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer. ADMET and DMPK, [S. l.], v. 4, n. 3, p. 186–211, 2016. DOI: 10.5599/admet.4.3.337. Disponível em: https://pub.iapchem.org/ojs/index.php/admet/article/view/337. Acesso em: 31 jul. 2026.